SCHEDULE 13G/A: Deep Track Capital Divests Entire Stake in Pyxis Oncology, Filing Shows 0% Beneficial Ownership
Schedule 13G Amendment
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G indicating they no longer hold any beneficial ownership in Pyxis Oncology, Inc. as of December 31, 2024.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Pyxis Oncology, Inc.
- As of December 31, 2024, the reporting persons collectively hold 0.00 shares, representing 0.00% of Pyxis Oncology, Inc.'s Common Stock.
- This filing indicates a complete divestment or reduction below the reporting threshold from their previous holdings.
- The filing states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
- Pyxis Oncology, Inc. had 59,465,729 Common Stock outstanding as of November 11, 2024, based on the issuer's 10-Q filed on November 12, 2024.
Sentiment
Score: 3
Explanation: The sentiment is negative as a significant institutional investor has reduced its stake to zero, which can be interpreted as a loss of confidence in the company's future prospects by that investor.
Negatives
- The filing indicates that Deep Track Capital and its affiliates, previously a reporting entity, have reduced their beneficial ownership in Pyxis Oncology, Inc. to 0%, which could be interpreted as a loss of confidence or a strategic exit by a significant investor.
Future Outlook
The document does not provide any forward-looking statements or guidance from Pyxis Oncology, Inc. or the reporting persons regarding the issuer's future performance.
Industry Context
This filing is a standard disclosure of a change in beneficial ownership by an institutional investor in a biotechnology company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The divestment by a significant institutional investor could lead to negative market sentiment and potentially impact the share price, especially if other investors interpret it as a lack of confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-11-11 | Date as of which Pyxis Oncology, Inc. had 59,465,729 Common Stock outstanding, according to its 10-Q filing. |
| 2024-11-12 | Date Pyxis Oncology, Inc. filed its 10-Q with the SEC, reporting outstanding shares. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G Amendment, indicating 0% beneficial ownership. |
| 2025-02-14 | Date the Schedule 13G Amendment was signed and filed by David Kroin on behalf of the reporting persons. |
Keywords
Pyxis Oncology, Deep Track Capital, Schedule 13G, Beneficial Ownership, Stock Divestment, Biotechnology, SEC Filing, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.